Cosentyx significantly improves itching, pain, and scaling

[Fred]

Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor to be approved in Europe and this approval marks a significant milestone in the treatment of psoriasis, providing a new and important "FIRST LINE" biologic treatment option for patients.

Currently, all biologic treatments for psoriasis, including anti-tumor necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe.

This is what I understand from a article I read regarding treatment for P that cosentyx does not have a line of meds to complete first, which is usually required by insurance companies or most health coverage available.

I doubt very much that Europe will be using it as a First Line. Most of Europe follow the same protocol. And Bio's are last on the list.